HUE056878T2 - Hiperlipidémia kezelési módszerei ANGPTL8 inhibitorral és ANGPTL3 inhibitorral - Google Patents
Hiperlipidémia kezelési módszerei ANGPTL8 inhibitorral és ANGPTL3 inhibitorralInfo
- Publication number
- HUE056878T2 HUE056878T2 HUE17719107A HUE17719107A HUE056878T2 HU E056878 T2 HUE056878 T2 HU E056878T2 HU E17719107 A HUE17719107 A HU E17719107A HU E17719107 A HUE17719107 A HU E17719107A HU E056878 T2 HUE056878 T2 HU E056878T2
- Authority
- HU
- Hungary
- Prior art keywords
- inhibitor
- methods
- angptl8
- angptl3
- treating hyperlipidemia
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 2
- 208000031226 Hyperlipidaemia Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662319980P | 2016-04-08 | 2016-04-08 | |
| US201762453110P | 2017-02-01 | 2017-02-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE056878T2 true HUE056878T2 (hu) | 2022-03-28 |
Family
ID=58610026
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE17719107A HUE056878T2 (hu) | 2016-04-08 | 2017-04-07 | Hiperlipidémia kezelési módszerei ANGPTL8 inhibitorral és ANGPTL3 inhibitorral |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US20170291937A1 (enExample) |
| EP (1) | EP3439689B1 (enExample) |
| JP (1) | JP6964090B2 (enExample) |
| KR (1) | KR20180132843A (enExample) |
| CN (1) | CN109789194B (enExample) |
| AU (1) | AU2017248356A1 (enExample) |
| CA (1) | CA3020175A1 (enExample) |
| CY (1) | CY1124902T1 (enExample) |
| ES (1) | ES2896107T3 (enExample) |
| HR (1) | HRP20212028T1 (enExample) |
| HU (1) | HUE056878T2 (enExample) |
| IL (1) | IL262130A (enExample) |
| LT (1) | LT3439689T (enExample) |
| MD (1) | MD3439689T2 (enExample) |
| MX (1) | MX386832B (enExample) |
| PL (1) | PL3439689T3 (enExample) |
| PT (1) | PT3439689T (enExample) |
| RS (1) | RS62769B1 (enExample) |
| SI (1) | SI3439689T1 (enExample) |
| SM (1) | SMT202200016T1 (enExample) |
| WO (1) | WO2017177181A1 (enExample) |
| ZA (1) | ZA201806264B (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR087329A1 (es) | 2011-06-17 | 2014-03-19 | Regeneron Pharma | Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana |
| TW201713690A (zh) | 2015-08-07 | 2017-04-16 | 再生元醫藥公司 | 抗ａｎｇｐｔｌ８抗體及其用途 |
| EA201891979A1 (ru) | 2016-03-03 | 2019-01-31 | Ридженерон Фармасьютикалз, Инк. | Способы лечения пациентов с гиперлипидемией введением ингибитора pcsk9 в комбинации с ингибитором angptl3 |
| IL262591B (en) * | 2016-04-28 | 2022-07-01 | Regeneron Pharma | Treatment methods for patients with hereditary high blood cholesterol |
| CN110036029A (zh) * | 2016-11-17 | 2019-07-19 | 瑞泽恩制药公司 | 用抗angptl8抗体处理肥胖的方法 |
| WO2019094533A1 (en) * | 2017-11-10 | 2019-05-16 | Ngm Biopharmaceuticals Inc | Angptl8-binding agents and methods of use thereof |
| US11977081B2 (en) | 2017-12-18 | 2024-05-07 | Regeneron Pharmaceuticals, Inc. | ANGPTL8 assay and uses thereof |
| WO2020104649A2 (en) * | 2018-11-23 | 2020-05-28 | Sanofi | Novel rna compositions and methods for inhibiting angptl8 |
| TWI747098B (zh) * | 2018-12-21 | 2021-11-21 | 美商美國禮來大藥廠 | 抗angptl3/8複合物抗體及其使用方法 |
| CN112062845B (zh) * | 2019-06-10 | 2022-09-02 | 山东博安生物技术股份有限公司 | Angptl3结合片段及其用途 |
| CN110596399B (zh) * | 2019-08-29 | 2022-07-22 | 首都医科大学附属北京安贞医院 | 检测血管生成素样蛋白8含量的物质的应用 |
| CN110613847B (zh) * | 2019-10-23 | 2022-02-11 | 北京市心肺血管疾病研究所 | 一种抑制血管生成素样蛋白8的物质的应用 |
| CN110694068A (zh) * | 2019-11-06 | 2020-01-17 | 北京市心肺血管疾病研究所 | 一种抑制血管生成素样蛋白8的物质的应用 |
| CN110694067A (zh) * | 2019-11-06 | 2020-01-17 | 首都医科大学附属北京安贞医院 | 一种抑制血管生成素样蛋白8的物质的应用 |
| CN110938144B (zh) * | 2019-11-27 | 2022-07-26 | 复旦大学附属儿科医院 | 一种抗angptl3单克隆抗体及其在制备治疗肾病综合征药物中的用途 |
| CN111135303A (zh) * | 2020-01-17 | 2020-05-12 | 北京市心肺血管疾病研究所 | 一种抑制血管生成素样蛋白8的物质的应用 |
| KR20220131935A (ko) * | 2020-01-22 | 2022-09-29 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | 항angptl3 항체 및 이의 용도 |
| CN116096365A (zh) * | 2020-08-07 | 2023-05-09 | 瑞泽恩制药公司 | 涉及angptl3抑制剂的治疗难治性高胆固醇血症的方法 |
| EP4453210A1 (en) * | 2021-12-22 | 2024-10-30 | Regeneron Pharmaceuticals, Inc. | Treatment of kidney diseases with angiopoietin like 3 (angptl3) inhibitors |
| CN114671943B (zh) * | 2022-04-29 | 2023-05-05 | 四川大学 | 一种鱼类摄食调控蛋白的制备和应用 |
| KR20250010670A (ko) * | 2022-05-16 | 2025-01-21 | 시티 오브 호프 | 항-cd84 항체 및 이의 용도 |
| CN115947779B (zh) * | 2022-08-10 | 2025-04-25 | 武汉安砥生物科技有限公司 | 针对人血管生成素样蛋白3的免疫原性肽段及其载体疫苗和用途 |
| WO2024130165A1 (en) * | 2022-12-16 | 2024-06-20 | Regeneron Pharmaceuticals, Inc. | Angptl3 inhibitors for triglyceride reduction in multifactorial chylomicronemia syndrome |
| WO2024227059A2 (en) * | 2023-04-27 | 2024-10-31 | Aligos Therapeutics, Inc. | Short interfering nucleic acid (sina) molecules targeting angptl 3 and angptl 8 and methods of using the same |
| CN117535353A (zh) * | 2023-10-11 | 2024-02-09 | 首都医科大学附属北京潞河医院 | 一种糖尿病视网膜病变模型的建立方法及应用 |
| CN119039435A (zh) * | 2024-09-21 | 2024-11-29 | 复旦大学附属儿科医院 | 一种抗angptl3人源化单抗及其应用 |
| CN119367545B (zh) * | 2025-01-02 | 2025-04-08 | 山东第一医科大学(山东省医学科学院) | 靶向干预ANGPTL8 mRNA在制备治疗高同型半胱氨酸血症药物中的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| WO2007143168A2 (en) | 2006-06-02 | 2007-12-13 | Regeneron Pharmaceuticals, Inc. | High affinity antibodies to human il-6 receptor |
| WO2012168491A1 (en) | 2011-06-10 | 2012-12-13 | Novartis Ag | Pharmaceutical formulations of pcsk9 antagonists |
| AR087329A1 (es) * | 2011-06-17 | 2014-03-19 | Regeneron Pharma | Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| EA039663B1 (ru) | 2012-05-03 | 2022-02-24 | Амген Инк. | Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств |
| US10071139B2 (en) * | 2014-10-03 | 2018-09-11 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of conditions associated with elevated triglycerides with an ANGPTL8 polypeptide fragment |
| TW201713690A (zh) * | 2015-08-07 | 2017-04-16 | 再生元醫藥公司 | 抗ａｎｇｐｔｌ８抗體及其用途 |
-
2017
- 2017-04-07 RS RS20211568A patent/RS62769B1/sr unknown
- 2017-04-07 ES ES17719107T patent/ES2896107T3/es active Active
- 2017-04-07 CA CA3020175A patent/CA3020175A1/en active Pending
- 2017-04-07 HR HRP20212028TT patent/HRP20212028T1/hr unknown
- 2017-04-07 PT PT177191079T patent/PT3439689T/pt unknown
- 2017-04-07 KR KR1020187032369A patent/KR20180132843A/ko not_active Abandoned
- 2017-04-07 EP EP17719107.9A patent/EP3439689B1/en active Active
- 2017-04-07 PL PL17719107T patent/PL3439689T3/pl unknown
- 2017-04-07 WO PCT/US2017/026679 patent/WO2017177181A1/en not_active Ceased
- 2017-04-07 LT LTEPPCT/US2017/026679T patent/LT3439689T/lt unknown
- 2017-04-07 AU AU2017248356A patent/AU2017248356A1/en not_active Abandoned
- 2017-04-07 SM SM20220016T patent/SMT202200016T1/it unknown
- 2017-04-07 HU HUE17719107A patent/HUE056878T2/hu unknown
- 2017-04-07 CN CN201780035121.1A patent/CN109789194B/zh not_active Expired - Fee Related
- 2017-04-07 MX MX2018012221A patent/MX386832B/es unknown
- 2017-04-07 SI SI201730953T patent/SI3439689T1/sl unknown
- 2017-04-07 US US15/482,499 patent/US20170291937A1/en not_active Abandoned
- 2017-04-07 JP JP2018552824A patent/JP6964090B2/ja active Active
- 2017-04-07 MD MDE20190190T patent/MD3439689T2/ro not_active IP Right Cessation
-
2018
- 2018-09-18 ZA ZA2018/06264A patent/ZA201806264B/en unknown
- 2018-10-04 IL IL262130A patent/IL262130A/en unknown
-
2019
- 2019-11-15 US US16/685,876 patent/US20200377583A1/en not_active Abandoned
-
2022
- 2022-01-07 US US17/571,286 patent/US20220127348A1/en not_active Abandoned
- 2022-01-10 CY CY20221100023T patent/CY1124902T1/el unknown
-
2024
- 2024-08-12 US US18/801,099 patent/US20250066463A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PT3439689T (pt) | 2021-11-04 |
| ZA201806264B (en) | 2019-07-31 |
| CA3020175A1 (en) | 2017-10-12 |
| CN109789194B (zh) | 2022-08-02 |
| LT3439689T (lt) | 2021-11-10 |
| CY1124902T1 (el) | 2023-01-05 |
| JP6964090B2 (ja) | 2021-11-10 |
| US20200377583A1 (en) | 2020-12-03 |
| EP3439689B1 (en) | 2021-10-13 |
| MX386832B (es) | 2025-03-19 |
| KR20180132843A (ko) | 2018-12-12 |
| WO2017177181A1 (en) | 2017-10-12 |
| JP2019513751A (ja) | 2019-05-30 |
| MD3439689T2 (ro) | 2021-12-31 |
| CN109789194A (zh) | 2019-05-21 |
| PL3439689T3 (pl) | 2022-01-31 |
| US20250066463A1 (en) | 2025-02-27 |
| AU2017248356A1 (en) | 2018-10-25 |
| MX2018012221A (es) | 2019-02-13 |
| EP3439689A1 (en) | 2019-02-13 |
| SI3439689T1 (sl) | 2021-12-31 |
| HRP20212028T1 (hr) | 2022-04-01 |
| SMT202200016T1 (it) | 2022-03-21 |
| US20220127348A1 (en) | 2022-04-28 |
| US20170291937A1 (en) | 2017-10-12 |
| ES2896107T3 (es) | 2022-02-23 |
| IL262130A (en) | 2018-11-29 |
| RS62769B1 (sr) | 2022-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL262130A (en) | Methods for treating excess fat in the blood using angptl8 inhibitor and angptl3 inhibitor | |
| SG10201913085TA (en) | Methods and compositions for treating a serpinc1-associated disorder | |
| IL255463A (en) | Methods and kits for treating depression | |
| IL261586B (en) | A selective bromodomain inhibitor for bdii | |
| HUE056652T2 (hu) | Bevonóberendezés és annak mûködési eljárása | |
| GB201605126D0 (en) | Inhibitors and their uses | |
| PT3448516T (pt) | Aparelhos de fototerapia | |
| IL263330B (en) | Device and method for coordinating muzzle sight | |
| GB201601942D0 (en) | Cache and method | |
| IL255023A0 (en) | Methods of treating cancer with stat3 pathway inhibitor and kinase inhibitor | |
| GB201501093D0 (en) | Auto-focussing method and device | |
| IL254003A0 (en) | Improved Hemorrhoid Treatment and Reloading Device | |
| IL273155A (en) | Methods for treating depression and major depressive disorders | |
| ZA202000407B (en) | Device and method for treating must | |
| GB201702010D0 (en) | Oven tray and method | |
| IL247379A0 (en) | A method for treating depression and major depressive disorder | |
| PL3325985T3 (pl) | Urządzenie do dozymetrii elektromagnetycznej i powiązany sposób | |
| PL3059631T3 (pl) | Urządzenia i sposoby dostarczania światła | |
| GB201609402D0 (en) | Materials and methods for treating cancer | |
| IL264014B (en) | Device and method for orientation | |
| HK40001111A (en) | Methods for treating hyperlipidemia with an angptl8 inhibitor and an angptl3 inhibitor | |
| ZA201807614B (en) | Bromodomain inhibitors | |
| GB2548916B (en) | Muzzle and headcollar | |
| GB201720089D0 (en) | Means and methods for treating cancer | |
| GB201706821D0 (en) | Compounds and methods for treating obesity |